Weidong Yin
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Post-exposure prophylaxis with SA58 (anti-SARS-COV-2 monoclonal antibody) nasal spray for the prevention of symptomatic COVID-19 in healthy adult workers: a randomized, single-blind, placebo-controlled clinical study.
Journal: Emerging microbes & infections
Published: May 09, 2023
Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials.
Journal: The Lancet. Infectious diseases
Published: September 15, 2021
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Journal: The Lancet. Infectious diseases
Published: November 18, 2020
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Journal: The Lancet. Infectious diseases
Published: September 14, 2020
Development of an inactivated vaccine candidate for SARS-CoV-2.
Journal: Science (New York, N.Y.)
Published: April 10, 2020
Immunogenicity and Safety of a Sabin Strain-Based Inactivated Polio Vaccine: A Phase 3 Clinical Trial.
Journal: The Journal of infectious diseases
Published: October 18, 2018
Safety, immunogenicity and cross-reactivity of a Northern hemisphere 2013-2014 seasonal trivalent inactivated split influenza virus vaccine, Anflu®.
Journal: Human vaccines & immunotherapeutics
Published: March 03, 2016
Last Updated: 09/26/2026